Evidence map›Paper›PMID 22027386›Full record

ArticleHuman immunology2012

Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice.

Hua Cong, Ernest J Mui, William H Witola, John Sidney, Jeff Alexander, Alessandro Sette, Ajesh Maewal, Kamal El Bissati, Ying Zhou, Yasuhiro Suzuki and 6 more

Open access · greenAbstract read
In one paragraph

Article in Human immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.2field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Key Limitations and New Insights Into theFrontiers in cellular and infection microbiology · 2020
    Review
  6. Review
  7. Targeted Delivery ofFrontiers in immunology · 2018
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Hua CongDepartment of Surgery, The University of Chicago, Chicago, Illinois 60637, USA.
Ernest J Mui
William H Witola
John Sidney
Jeff Alexander
Alessandro Sette
Ajesh Maewal
Kamal El Bissati
Ying Zhou
Yasuhiro Suzuki
Daniel Lee
Stuart Woods
Caroline Sommerville
Fiona L Henriquez
Craig W Roberts
Rima McLeod
University of Chicago · USUniversity of Strathclyde · GBLa Jolla Institute for Immunology · USSynthetic Biologics (United States) · USUniversity of Kentucky · USUniversity of the West of Scotland · GB

Funding

Towards a Vaccine to Prevent ToxoplasmosisU01AI077887 · NIAID · UNIVERSITY OF CHICAGO · PI MCLEOD, RIMA L · 2008 to 2012
$4.2M
TREATMENT OF CONGENITAL TOXOPLASMOSISR01AI027530 · NIAID · UNIVERSITY OF CHICAGO · PI MCLEOD, RIMA L · 1989 to 2010
$2.8M
NIAID NIH HHS R01 AI027530NIAID NIH HHS U01 AI077887NIAID NIH HHS U01AI77887
6 · The paper itself

Abstract

The ability of CD8(+) T cells to act as cytolytic effectors and produce interferon-γ (IFN-γ) was demonstrated to mediate resistance to Toxoplasma gondii in murine models because of the recognition of peptides restricted by murine major histocompatibility complex (MHC) class I molecules. However, no T gondii-specific HLA-B07-restricted peptides were proven protective against T gondii. Recently, 2 T gondii-specific HLA-B*0702-restricted T cell epitopes, GRA7(20-28) (LPQFATAAT) and GRA3(27-35) (VPFVVFLVA), displayed high-affinity binding to HLA-B*0702 and elicited IFN-γ from peripheral blood mononuclear cells of seropositive HLA-B*07 persons. Herein, these peptides were evaluated to determine whether they could elicit IFN-γ in splenocytes of HLA-B*0702 transgenic mice when administered with adjuvants and protect against subsequent challenge. Peptide-specific IFN-γ-producing T cells were identified by enzyme-linked immunosorbent spot and proliferation assays utilizing splenic T lymphocytes from human lymphocyte antigen (HLA) transgenic mice. When HLA-B*0702 mice were immunized with one of the identified epitopes, GRA7(20-28) in conjunction with a universal CD4(+) T cell epitope (PADRE) and adjuvants (CD4(+) T cell adjuvant, GLA-SE, and TLR2 stimulatory Pam(2)Cys for CD8(+) T cells), this immunization induced CD8(+) T cells to produce IFN-γ and protected mice against high parasite burden when challenged with T gondii. This work demonstrates the feasibility of bioinformatics followed by an empiric approach based on HLA binding to test this biologic activity for identifying protective HLA-B*0702-restricted T gondii peptides and adjuvants that elicit protective immune responses in HLA-B*0702 mice.

Indexed as

Adjuvants, ImmunologicAmino Acid SequenceAnimalsCD8-Positive T-LymphocytesCell ProliferationCells, CulturedEnzyme-Linked Immunosorbent AssayEpitopes, T-LymphocyteFemaleHLA-B7 AntigenInterferon-gammaMaleMiceMice, Inbred BALB CMice, Inbred C57BLMice, TransgenicAdjuvants, ImmunologicEpitopes, T-LymphocyteHLA-B*07:02 antigenHLA-B7 AntigenInterferon-gammaPeptidesVaccines, Subunit

Identifiers

PMID22027386
PMCPMC3246109
OpenAlexW1990897349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.